Cargando…

Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is a subset of breast cancer with aggressive characteristics and few therapeutic options. The lack of an appropriate therapeutic target is a challenging issue in treating TNBC. Although a high level expression of epidermal growth factor receptor (EGFR) has been a...

Descripción completa

Detalles Bibliográficos
Autores principales:	You, Kyu Sic, Yi, Yong Weon, Cho, Jeonghee, Park, Jeong-Soo, Seong, Yeon-Sun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233743/ https://www.ncbi.nlm.nih.gov/pubmed/34207383 http://dx.doi.org/10.3390/ph14060589

Ejemplares similares

Inhibition of IκB Kinase Is a Potential Therapeutic Strategy to Circumvent Resistance to Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer Cells
por: Yi, Yong Weon, et al.
Publicado: (2022)

Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells
por: You, Kyu Sic, et al.
Publicado: (2021)

Mutations of the Epidermal Growth Factor Receptor Gene in Triple-Negative Breast Cancer
por: Kim, Aeri, et al.
Publicado: (2017)

Ribosomal Protein S6: A Potential Therapeutic Target against Cancer?
por: Yi, Yong Weon, et al.
Publicado: (2021)

Epidermal Growth Factor Receptor Expression in Triple Negative and Nontriple Negative Breast Carcinomas
por: Changavi, Arathi A, et al.
Publicado: (2015)

Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6
por: YI, YONG WEON, et al.
Publicado: (2015)

Lack of epidermal growth factor receptor (EGFR)-activating mutations in triple-negative breast cancer in China
por: Cao, Wen-Ming, et al.
Publicado: (2015)

Development of Cyclic Peptides Targeting the Epidermal Growth Factor Receptor in Mesenchymal Triple-Negative Breast Cancer Subtype
por: Nisticò, Nancy, et al.
Publicado: (2023)

Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells
por: Yi, Yong Weon, et al.
Publicado: (2013)

Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy
por: Teng, Yvonne Hui-Fang, et al.
Publicado: (2011)

Triple-Negative Metaplastic Breast Carcinoma: Association of Epidermal Growth Factor Receptor Expression With Prognostic Parameters and Clinical Outcome
por: Munawar, Shahzeb, et al.
Publicado: (2021)

Epidermal growth factor receptor (EGFR) expression in the serum of patients with triple-negative breast carcinoma: prognostic value of this biomarker
por: de Araújo, Rogério Agenor, et al.
Publicado: (2022)

Hormonal Receptors, Human Epidermal Growth Factor Receptor-2 and Triple Negative Immunohistochemical Typing in Women with Breast Cancer in Kampala, Uganda
por: Mlole, Angela T, et al.
Publicado: (2020)

Glut1 promotes cell proliferation, migration and invasion by regulating epidermal growth factor receptor and integrin signaling in triple-negative breast cancer cells
por: Oh, Sunhwa, et al.
Publicado: (2017)

Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2023)

Epidermal growth factor receptor (EGFR) gene alteration and protein overexpression in Malaysian triple-negative breast cancer (TNBC) cohort
por: Zakaria, Zubaidah, et al.
Publicado: (2019)

Fibrinogen/Albumin Ratio (FAR) in Patients with Triple Negative Breast Cancer and Its Relationship with Epidermal Growth Factor Receptor Expression
por: Gao, Wenbo, et al.
Publicado: (2021)

Dipalmitoylphosphatidic acid inhibits tumor growth in triple-negative breast cancer
por: Zhang, Qian-Qian, et al.
Publicado: (2017)

Lycopene Inhibits Activation of Epidermal Growth Factor Receptor and Expression of Cyclooxygenase-2 in Gastric Cancer Cells
por: Han, Hwana, et al.
Publicado: (2019)

Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants
por: Park, Angela K.J., et al.
Publicado: (2015)

Therapeutic Implications of the Drug Resistance Conferred by Extracellular Vesicles Derived from Triple-Negative Breast Cancer Cells
por: Yi, Yong Weon
Publicado: (2023)

Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer
por: Hamilton, Nalo, et al.
Publicado: (2017)

SH003 and Docetaxel Show Synergistic Anticancer Effects by Inhibiting EGFR Activation in Triple-Negative Breast Cancer
por: Choi, Yu-Jeong, et al.
Publicado: (2022)

Adaptation to Hypoxia May Promote Therapeutic Resistance to Androgen Receptor Inhibition in Triple-Negative Breast Cancer
por: Jinna, Nikita, et al.
Publicado: (2022)

Targeting epidermal growth factor‐overexpressing triple‐negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor
por: Liu, Yan, et al.
Publicado: (2020)

KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene
por: Roberts, Melyssa S., et al.
Publicado: (2020)

Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2021)

The prognostic and predictive significance of cytokeratin 5/6 and epidermal growth factor receptor in metastatic triple-negative breast cancer treated with maintenance capecitabine
por: Zhu, Yiping, et al.
Publicado: (2021)

Targeted therapy of triple negative MDA-MB-468 breast cancer with curcumin delivered by epidermal growth factor-conjugated phospholipid nanoparticles
por: Jung, Kyung-Ho, et al.
Publicado: (2018)

Knockdown of SPON2 inhibits the growth of triple-negative breast cancer
por: Hu, Xueyi, et al.
Publicado: (2023)

β-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in triple-negative breast cancer cells
por: Yi, Yong Weon, et al.
Publicado: (2015)

Inhibiting Epidermal Growth Factor Receptor at a Distance
por: Sinclair, Julie K.-L., et al.
Publicado: (2014)

Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer
por: Kung, Che-Pei, et al.
Publicado: (2020)

Nuclear epidermal growth factor receptor as a therapeutic target
por: Atwell, Benjamin, et al.
Publicado: (2023)

Ferroptosis and triple-negative breast cancer: Potential therapeutic targets
por: Xu, Na, et al.
Publicado: (2022)

Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met
por: Mueller, Kelly L, et al.
Publicado: (2012)

Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers
por: Toyama, Tatsuya, et al.
Publicado: (2008)

Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability
por: Powell, Catherine A., et al.
Publicado: (2015)

Tumor suppressor miR-218 directly targets epidermal growth factor receptor (EGFR) expression in triple-negative breast cancer, sensitizing cells to irradiation
por: Wischmann, Franz-Josef, et al.
Publicado: (2023)

Disruption of STAT3-DNMT1 interaction by SH-I-14 induces re-expression of tumor suppressor genes and inhibits growth of triple-negative breast tumor
por: Kang, Hyo Jin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_s0418d0aho5ibhgn7hdmpfom36